Physician profile
Robin T Watson
NPI 1205386349
$4,851.74
in general payments reported to CMS, 2019-2025
22 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $862 · 2022: $575 · 2023: $1,060 · 2024: $1,013 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $930.90 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $628.82 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $481.96 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $418.21 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $404.42 | 2021-2025 | Fanapt |
| Abbvie INC. | $370.51 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $362.57 | 2021-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $325.12 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $224.68 | 2021-2023 | Invega Trinza, Invega Sustenna |
| Lundbeck LLC | $146.21 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $98.92 | 2025 | |
| Axsome Therapeutics, INC. | $88.88 | 2023-2024 | Auvelity |
| Eisai INC. | $66.75 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.21 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $49.91 | 2024-2025 | Cobenfy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $41.63 | 2023-2025 | Perseris, Sublocade |
| Ironshore Pharmaceuticals INC. | $37.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.62 | 2022-2024 | Quviviq |
| Abbott Laboratories | $29.54 | 2022 | |
| Novo Nordisk INC | $19.25 | 2021 | |
| Lilly USA, LLC | $18.60 | 2025 | Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $17.00 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.